BioPharma Dive ٦ أبريل ٢٠٢٦ Under-the-skin Tepezza comparable to infused version in key study, Amgen says
BioPharma Dive ٤ فبراير ٢٠٢٦ Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan